NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00150670,Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer,https://clinicaltrials.gov/study/NCT00150670,,COMPLETED,This study aimed to verify the survival benefit of TS-1 plus CDDP combination chemotherapy compared with the monotherapy by TS-1 alone.,NO,Gastric Cancer,DRUG: TS-1 and cisplatin|DRUG: TS-1,"Overall survival, every course for first three courses, then every other course","Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile, every course for first three courses, then every other course",,"Taiho Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,300,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,91023039,2002-03,2006-12,2006-12,2005-09-08,,2011-07-07,"East Hospital, Kitasato University, 2-1-1, Asamizodai, Sagamihara, Kanagawa, Japan",
